GLP1R and obesity due to melanocortin 4 receptor deficiency: This suggests GLP-1 receptor agonists may be particularly valuable in MHO individuals, whose arrhythmogenic risk may be driven more by obesity-related inflammation and fat distribution than by traditional metabolic pathways.